137310.KS
SD BioSensor, Inc
KSC · Healthcare · Medical - Instruments & Supplies · KR
KRW 6,180.00
+2.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 738.8B | 710.6B | 694.6B | 655.7B | 2932.0B |
| Cost of Revenue | 536.9B | 484.7B | 355.2B | 533.2B | 1539.0B |
| Gross Profit | 201.8B | 225.9B | 339.4B | 122.4B | 1393.0B |
| Operating Expenses | |||||
| R&D Expense | 83.6B | 78.1B | 87.9B | 64.2B | 45.8B |
| SG&A Expense | 129.2B | 105.7B | 84.4B | 111.1B | 88.3B |
| General & Admin Expense | 20.9B | 30.6B | 23.7B | 23.0B | 12.6B |
| Selling & Marketing Expense | 53.0B | 75.1B | 60.7B | 88.1B | 75.7B |
| Other Expenses | 154.9B | 125.0B | 221.1B | 198.8B | 112.3B |
| Total Operating Expenses | 344.5B | 308.7B | 393.4B | 374.1B | 246.4B |
| Cost and Expenses | 804.6B | 791.5B | 748.6B | 903.8B | 1785.4B |
| Operating Income (EBIT) | (65.8B) | (82.9B) | (54.1B) | (248.1B) | 1146.6B |
| Non-Operating | |||||
| Interest Income | 22.1B | 24.2B | 22.3B | 23.5B | 26.5B |
| Interest Expense | 90.6B | 108.2B | 68.6B | 49.2B | 994.1M |
| Net Interest Income | (68.4B) | (84.0B) | (46.3B) | (25.7B) | 25.5B |
| Other Non-Op Income/Expense | (728.9B) | (842.5B) | (165.1B) | (190.5B) | 95.5B |
| Non-Operating Income (excl Interest) | 709.0B | — | 92.6B | 141.3B | (96.5B) |
| EBT (Pre-Tax Income) | (794.7B) | (923.5B) | (219.2B) | (438.6B) | 1242.1B |
| Income Tax Expense | (63.6B) | (402.0B) | (121.0B) | 29.3B | 333.3B |
| Bottom Line | |||||
| Net Income | (729.5B) | (521.4B) | (98.4B) | (467.7B) | 911.4B |
| Earnings from Cont. Ops | (731.1B) | (521.4B) | (98.1B) | (467.9B) | 911.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (729.5B) | (521.4B) | (98.4B) | (467.7B) | 911.4B |
| Per Share | |||||
| Basic EPS | (₩6,064) | (₩4,283) | (₩805) | (₩4,219) | ₩8,997 |
| Diluted EPS | (₩6,064) | (₩4,283) | (₩805) | (₩4,219) | ₩8,997 |
| Revenue Per Share | ₩6,176 | ₩5,836 | ₩5,684 | ₩5,914 | ₩28,944 |
| Shares | |||||
| Basic Shares Outstanding | 119.6M | 121.7M | 122.2M | 110.9M | 101.3M |
| Diluted Shares Outstanding | 119.6M | 121.7M | 122.2M | 110.9M | 101.3M |
| Profitability Metrics | |||||
| EBITDA | (19.7B) | 51.4B | (5.4B) | (250.9B) | 1283.9B |
| D&A | 125.7B | 134.3B | 141.7B | 137.5B | 40.8B |
| EBIT | (46.8B) | (82.9B) | (147.1B) | (389.4B) | 1243.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026